Form D · Biotechnology
PepGen Inc.
Boston, MA · CIK 0001835597
Offering snapshot reported Aug 6, 2021 · SEC filing
- Reported sold
- $112M Offering amount: $112M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2021 | Initial | $112,499,887 | No comparison | Not reported | SEC filing |
| Dec 9, 2020 | Initial | $14,366,712 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-409137
Source: Form D, filed Aug 6, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher Ashton | Director |
| Ramin Farzaneh Far | Director |
| Caroline Godfrey | Director, Executive |
| Heidi Henson | Director |
| James Mc Arthur | Director, Executive |
| Joshua Resnick | Director |
| Josh Resnick | Director |
| Matthew Wood | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Marina Park Drive, Suite 900
Boston, MA, 02210
Boston, MA, 02210